These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11256156)

  • 21. [The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis].
    Popova EV; Boĭko AN; Davydovskaia MV; Demina TL; Kukel' TM; Lashch NIu; Popova NF; Khachanova NV; Shchur SG; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10 Pt 2):93-6. PubMed ID: 24300821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis.
    Pulicken M; Bash CN; Costello K; Said A; Cuffari C; Wilterdink JL; Rogg JM; Mills P; Calabresi PA
    Mult Scler; 2005 Apr; 11(2):169-74. PubMed ID: 15794390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS.
    Pöllmann W; Erasmus LP; Feneberg W; Then Bergh F; Straube A
    Neurology; 2002 Aug; 59(4):636-9. PubMed ID: 12196668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Electrophysiological, neuropsychological and clinical findings in multiple sclerosis patients receiving interferon beta-1b: a 1-year follow-up.
    Gerschlager W; Beisteiner R; Deecke L; Dirnberger G; Endl W; Kollegger H; Lindinger G; Vass K; Lang W
    Eur Neurol; 2000; 44(4):205-9. PubMed ID: 11096218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.
    Tremlett HL; Oger J
    Neurology; 2003 Aug; 61(4):551-4. PubMed ID: 12939437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Formation of neutralizing antibodies in therapy of multiple sclerosis with interferon beta-1b. Practical procedure in suspected therapeutic failure].
    Walther EU; Dang T; Hartung HP; Hohlfeld R
    Nervenarzt; 1997 Dec; 68(12):935-9. PubMed ID: 9465334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Education and self-management of interferon beta-1b therapy for multiple sclerosis.
    Keating MM; Ostby PL
    J Neurosci Nurs; 1996 Dec; 28(6):350-2, 357-8. PubMed ID: 9007762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for MS: considerations for managed care.
    Barnes CJ; Caon C; Foley JF; Friedman M; Menzin J; Nair KV; Nichols C; Olvey EL; Owens GM; Pill MW; Skrepnek GH; White LA; Zerkowski K
    J Manag Care Pharm; 2013; 19(1 Suppl A):S1-53. PubMed ID: 23383730
    [No Abstract]   [Full Text] [Related]  

  • 29. The role of interferons in the treatment of multiple sclerosis.
    Kelley CL
    J Neurosci Nurs; 1996 Apr; 28(2):114-20. PubMed ID: 8718760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson.
    Alsalameh S; Manger B; Kern P; Kalden J
    Arthritis Rheum; 1998 Apr; 41(4):754. PubMed ID: 9550494
    [No Abstract]   [Full Text] [Related]  

  • 31. Betaseron for multiple sclerosis. Implications for therapeutics.
    Rudick RA
    Arch Neurol; 1994 Feb; 51(2):125-8. PubMed ID: 8304836
    [No Abstract]   [Full Text] [Related]  

  • 32. [Interferons beta in patients with multiple sclerosis].
    Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
    [No Abstract]   [Full Text] [Related]  

  • 33. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS.
    Río J; Montalban X
    Neurology; 2000 Apr; 54(8):1710. PubMed ID: 10762530
    [No Abstract]   [Full Text] [Related]  

  • 35. [Pharmacological and clinical profile of IFNbeta-1a (Avonex IM Injection Syringe 30 microg].
    Sumino R
    Nihon Yakurigaku Zasshi; 2007 Mar; 129(3):209-17. PubMed ID: 17379973
    [No Abstract]   [Full Text] [Related]  

  • 36. Nursing management of MS patients receiving interferon beta-1b therapy.
    Costello K; Conway K
    Rehabil Nurs; 1997; 22(2):62-6, 81. PubMed ID: 9110845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
    Frese A; Bethke F; Lüdemann P; Stögbauer F
    Neurology; 1999 Nov; 53(8):1892-3. PubMed ID: 10563657
    [No Abstract]   [Full Text] [Related]  

  • 38. Experiences with interferon-beta-1b treatment in MS after three year follow-up.
    Bencsik K; Rajda C; Füvesi J; Járdánházy T; Török M; Vécsei L
    Swiss Med Wkly; 2002 May; 132(17-18):237. PubMed ID: 12087490
    [No Abstract]   [Full Text] [Related]  

  • 39. Interferon-beta treatment decreases cholesterol plasma levels in multiple sclerosis patients.
    Morra VB; Coppola G; Orefice G; De Michele G; Vacca G; Filla A; Bonavita V
    Neurology; 2004 Mar; 62(5):829-30. PubMed ID: 15007146
    [No Abstract]   [Full Text] [Related]  

  • 40. Interferon-beta1b in multiple sclerosis.
    Buttmann M; Rieckmann P
    Expert Rev Neurother; 2007 Mar; 7(3):227-39. PubMed ID: 17341170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.